Company: OSRH
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001213900-25-109054
Chunk: 37

Company: OSR Holdings, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 37
---
 and 2024 are calculated as follows:

    (Number of shares) 
    For the nine months ended
 September 30 

    2025  
    2024 
  
    Weighted average number of ordinary shares outstanding beginning 
     17,375,710  
     2,155,000 
  
    Diluted effect) Convertible bonds conversion effect 
     403,807  
     - 
  
    Diluted effect) Warrant conversion effect 
     5,338,855  
     - 
  
    Weighted average number of ordinary shares outstanding 
     23,118,372  
     2,155,000 

25

(23)
Commitment and contingencies

The Group has no pending litigation
cases arising in the ordinary course of business as of September 30, 2025 and December 31, 2024. The Parent has entered into various contractual
commitments related to the acquisition of VAXIMM including a future financial obligation of CHF 7,416 underlying as of September 30, 2025.
Meanwhile, both parties have agreed to remove section 6.1.3 of the license agreement that states that in the event of the Parent’s
sale to a third party, the Licensor shall reimburse the Licensee for reasonable costs and expenses incurred in the preparation, submission,
maintenance, prosecution, and enforcement process.

(24)
Segment reporting

The Group operates in one operating segment. Operating segments
are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision
maker (“CODM”) in deciding how to allocate resources and assessing performance. The Group’s CODM role is fulfilled by
the Executive Leadership Team, who allocates resources and assesses performance based upon consolidated financial information. The geographic
segments for the long-lived assets and ROU assets are disclosed below.

There are no external customers that account for more than
10% of sales for the reporting period.

(25)
Subsequent events

The Group has evaluated subsequent
events from the balance sheet date through November 3, 2025, the date at which the condensed consolidated financial statements were available
to be issued and determined that there are no other items to disclose, except the following:

●In October, the Group issued total of 2,001,571 shares under the warrants, to raise gross proceeds of
$900,707.

●In October, the Board of Directors of the